GLP-1R–Targeting Magnetic Nanoparticles for Pancreatic Islet Imaging
- Harvard Medical School, Boston, MA (United States). Dept. of Radiology. Athinoula A. Martinos Center for Biomedical Imaging. Molecular Imaging Lab.; DOE/OSTI
- Harvard Medical School, Boston, MA (United States). Dept. of Radiology. Athinoula A. Martinos Center for Biomedical Imaging. Molecular Imaging Lab.
- Harvard Medical School, Boston, MA (United States). Massachusetts General Hospital. Dept. of Radiology. Athinoula A. Martinos Center for Biomedical Imaging
- Harvard Medical School, Boston, MA (United States). Dept. of Radiology. Athinoula A. Martinos Center for Biomedical Imaging. Molecular Imaging Lab.; China Pharmaceutical Univ., Nanjing (China). School of Pharmacy. Center for Drug Discovery
Noninvasive assessment of pancreatic b-cell mass would tremendously aid in managing type 1 diabetes (T1D). Toward this goal, we synthesized an exendin-4 conjugated magnetic iron oxide–based nanoparticle probe targeting glucagon-like peptide 1 receptor (GLP1R), which is highly expressed on the surface of pancreatic b-cells. In vitro studies in βTC-6, the b-cell line, showed specific accumulation of the targeted probe (termed MN-Ex10-Cy5.5) compared with nontargeted (termed MN-Cy5.5). In vivo magnetic resonance imaging showed a significant transverse relaxation time (T2) shortening in the pancreata of mice injected with the MN-Ex10-Cy5.5 probe compared with control animals injected with the nontargeted probe at 7.5 and 24 h after injection. Furthermore, ΔT2 of the pancreata of prediabetic NOD mice was significantly higher than that of diabetic NOD mice after the injection of MN-Ex10-Cy5.5, indicating the decrease of probe accumulation in these animals due to β-cell loss. Of note, ΔT2 of prediabetic and diabetic NOD mice injected with MN-Cy5.5 was not significantly changed, reflecting the nonspecific mode of accumulation of nontargeted probe. We believe our results point to the potential for using this agent for monitoring the disease development and response of T1D to therapy.
- Research Organization:
- Massachusetts General Hospital, Boston, MA (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC), Biological and Environmental Research (BER). Biological Systems Science Division
- Grant/Contract Number:
- SC0008430
- OSTI ID:
- 1628017
- Journal Information:
- Diabetes, Journal Name: Diabetes Journal Issue: 5 Vol. 63; ISSN 0012-1797
- Publisher:
- American Diabetes AssociationCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
GLP-1 receptor antagonist as a potential probe for pancreatic {beta}-cell imaging
Substance P preserves pancreatic β-cells in type 1 and type 2 diabetic mice
Selective destruction of mouse islet beta cells by human T lymphocytes in a newly-established humanized type 1 diabetic model
Journal Article
·
Thu Nov 19 23:00:00 EST 2009
· Biochemical and Biophysical Research Communications
·
OSTI ID:22199885
Substance P preserves pancreatic β-cells in type 1 and type 2 diabetic mice
Journal Article
·
Tue May 15 00:00:00 EDT 2018
· Biochemical and Biophysical Research Communications
·
OSTI ID:23137158
Selective destruction of mouse islet beta cells by human T lymphocytes in a newly-established humanized type 1 diabetic model
Journal Article
·
Fri Sep 03 00:00:00 EDT 2010
· Biochemical and Biophysical Research Communications
·
OSTI ID:22202760